EMA accepts marketing authorisation application for anti-epileptic drug cenobamate
Cenobamate’s application was based on a global clinical trials programme enrolling over 1,900 adults with uncontrolled focal-onset seizures.
List view / Grid view
Cenobamate’s application was based on a global clinical trials programme enrolling over 1,900 adults with uncontrolled focal-onset seizures.
The bill includes $80 million funding for the US FDA to continue their COVID-19 response efforts and extra powers to modernise over-the-counter drug regulation.
During the COVID-19 pandemic, when many are in lockdown or self-isolating, mental health could suffer. This article suggests some ways to stay healthy over this period.
The enterprise announced it will donate two million hydroxychloroquine tablets and the same of matched placebo to the multi-national COPCOV study.
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
The FDA and EMA have announced which COVID-19 treatments and vaccines are currently in development, as well as how they are supporting clinical trials.
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
The European Medicines Agency (EMA) has advised consumers on how to recognise registered online pharmacies so they can avoid falsified medications.
Researchers in China administered COVID-19 patients with a mesenchymal stem cell therapy that demonstrated success at treating the condition.
The presence of female directors makes boards more likely to report lower-severity defects and faster to recall products with high-severity problems, suggests research.
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
The EMA has said that patients should continue to use angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), despite reports that these worsen COVID-19 infections.
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
A Phase II/III trial to study Kevzara (sarilumab) as a method to reduce the inflammatory response in the lungs of COVID-19 patients has begun outside of the US.